tiprankstipranks
Blurbs

Needham Remains a Buy on Evolus (EOLS)

Needham analyst Serge Belanger maintained a Buy rating on Evolus (EOLSResearch Report) today and set a price target of $18.00. The company’s shares closed last Tuesday at $10.57.

According to TipRanks.com, Belanger is a 2-star analyst with an average return of 0.1% and a 41.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus with a $15.20 average price target, representing a 20.8% upside. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $15.00 price target.

See the top stocks recommended by analysts >>

Evolus’ market cap is currently $734.8M and has a P/E ratio of -10.09.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Read More on EOLS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More